Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer
Open Access
- 27 August 2012
- Vol. 118 (23), 5937-5946
- https://doi.org/10.1002/cncr.27527
Abstract
BACKGROUND: Obesity has been associated with inferior outcomes in operable breast cancer, but the relation between body mass index (BMI) and outcomes by breast cancer subtype has not been previously evaluated. METHODS: The authors evaluated the relation between BMI and outcomes in 3 adjuvant trials coordinated by the Eastern Cooperative Oncology Group that included chemotherapy regimens with doxorubicin and cyclophosphamide, including E1199, E5188, and E3189. Results are expressed as hazard ratios (HRs) from Cox proportional hazards models (HR >1 indicates a worse outcome). All P values are 2‐sided. RESULTS: When evaluated as a continuous variable in trial E1199, increasing BMI within the obese (BMI, ≥30 kg/m2) and overweight (BMI, 25‐29.9 kg/m2) ranges was associated with inferior outcomes in hormone receptor‐positive, human epidermal growth receptor 2 (HER‐2)/neu‐negative disease for disease‐free survival (DFS; P = .0006) and overall survival (OS; P = .0007), but not in HER‐2/neu –overexpressing or triple‐negative disease. When evaluated as a categorical variable, obesity was associated with inferior DFS (HR, 1.24; 95% confidence interval [CI], 1.06‐1.46; P = .0008) and OS (HR, 1.37; 95% CI, 1.13‐1.67; P = .002) in hormone receptor‐positive disease, but not other subtypes. In a model including obesity, disease subtype, and their interaction, the interaction term was significant for OS (P = .02) and showed a strong trend for DFS (P = .07). Similar results were found in 2 other trials (E5188, E3189). CONCLUSIONS: In a clinical trial population that excluded patients with significant comorbidities, obesity was associated with inferior outcomes specifically in patients with hormone receptor‐positive operable breast cancer treated with standard chemohormonal therapy. Cancer 2012. © 2012 American Cancer Society.Keywords
This publication has 37 references indexed in Scilit:
- Fasting C-Peptide Levels and Death Resulting From All Causes and Breast Cancer: The Health, Eating, Activity, and Lifestyle StudyJournal of Clinical Oncology, 2011
- Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat DietNew England Journal of Medicine, 2008
- Weekly Paclitaxel in the Adjuvant Treatment of Breast CancerNew England Journal of Medicine, 2008
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Influence of a Diet Very High in Vegetables, Fruit, and Fiber and Low in Fat on Prognosis Following Treatment for Breast CancerJama-Journal Of The American Medical Association, 2007
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999